News and Publications September 20, 2023 Transimmune Secures $5m Funding to Enhance mRNA Vaccination Transimmune AG secures a $5M investment from the Bill & Melinda Gates Strategic Investment Fund to enhance mRNA vaccine potency using its physiologically induced dendritic cells (phDCs), starting with a therapeutic HIV vaccine. All Press Release News Publication Year 2023 2020 News 1st ARPA-H Grant: mRNA-Based Anti-Cancer and Anti-Microbial Vaccine Development ARPA-H awards its first-ever grant — $25M over three years to Yale, Emory and the University of Georgia to use designer mRNA to program dendritic cells for personalized cancer vaccines, with Transimmune's team providing key support. Press Release Transimmune selected for first ARPA-H grant Alongside Emory University, Yale University and University Of Georgia Publication Summary of Publications 1987–2020: Research history of ECP and Myeloid Activation
News 1st ARPA-H Grant: mRNA-Based Anti-Cancer and Anti-Microbial Vaccine Development ARPA-H awards its first-ever grant — $25M over three years to Yale, Emory and the University of Georgia to use designer mRNA to program dendritic cells for personalized cancer vaccines, with Transimmune's team providing key support.
Press Release Transimmune selected for first ARPA-H grant Alongside Emory University, Yale University and University Of Georgia
